XML 39 R30.htm IDEA: XBRL DOCUMENT v3.25.2
Short-Term Investments - Schedule of Fair Value of Common Shares (Details) - USD ($)
9 Months Ended 12 Months Ended
Jul. 31, 2025
Oct. 31, 2024
Polyrizon Ltd. – shares and warrants [Member]    
Schedule of Fair Value of Common Shares [Line Items]    
Beginning shares $ 289,388 [1]
Additions [1] 200,000 350,400
Disposals [1] (195,914)
Changes in fair value [1] (292,390) (61,012)
Ending shares [1] 1,084 289,388
Short-term Investment [Member]    
Schedule of Fair Value of Common Shares [Line Items]    
Beginning shares 289,388 86,112
Additions 200,000 350,400
Disposals (195,914) (78,500)
Changes in fair value (292,390) (68,624)
Ending shares 1,084 289,388
Xylo Technologies Ltd. – shares [Member]    
Schedule of Fair Value of Common Shares [Line Items]    
Beginning shares 86,112
Additions  
Disposals   (78,500)
Changes in fair value   (7,612)
Ending shares  
[1]

On October 30, 2024, the Company subscribed for 320 shares and 960 warrants (“October 2024 Polyrizon Warrants”) of Polyrizon Ltd. (“Polyrizon”) in Polyrizon’s initial public offering on the Nasdaq at a cost of $350,400. Each October 2024 Polyrizon Warrant can be exercised into one ordinary share of Polyrizon at an exercise price of $1,095.00 per share, subject to certain adjustments, include a cashless exercise mechanism. The Polyrizon Warrants expire on October 29, 2029.

 

During November 2024, the Company sold all the shares of Polyrizon that it received in Polyrizon’s initial ublic offering for total proceeds of $82,960.

 

On March 31, 2025, the Company subscribed for 866 shares of Polyrizon, 800 pre funded warrants to purchase shares of Polyrizon (“Polyrizon Pre-Funded Warrants”) and 1,666 warrants to purchase shares of Polyrizon (“March 2025 Polyrizon Warrants”) at an aggregate cost of $200,000 in a private placement (the “Polyrizon Private Placement”). In connection with the Polyrizon Private Placement, the Company exchanged the October 2024 Polyrizon Warrants for new warrants (the “Exchange Warrants”), which were substantially in the same form as the March 2025 Polyrizon Warrants. Each Polyrizon Pre-Funded Warrant can be exercised into one ordinary share of Polyrizon at an exercise price of $0.00001, subject to certain adjustments, including a cashless exercise mechanism, and each March 2025 Polyrizon Warrant and Exchange Warrant can be exercised into one ordinary share of Polyrizon at an exercise price of $300.00 per share subject to certain adjustments, including a cashless exercise mechanism. The March 2025 Polyrizon Warrants and Exchange Warrants have certain anti-dilution protection and expire on September 30, 2027.

 

On May 13, 2025, the Company exercised the Polyrizon Pre-Funded Warrants and received 800 Polyrizon shares.

 

On May 27, 2025, Polyrizon effected a reverse share split of its ordinary shares at the ratio of 1-for-250, such that each two hundred and fifty (250) ordinary shares, no par value, were consolidated into one (1) ordinary share, no par value. All the Polyrizon Shares and price per Polyrizon shares have been retroactively adjusted in these financial statements.

 

On May 30, 2025, the Company exercised the Exchange Warrants and the March 2025 Polyrizon Warrants in full   and received 98,705 Polyrizon shares, which were sold on June 18, 2025 and July 25, 2025 for an aggregate amount of $106,362, and accordingly, the Company recorded a realized loss of $63,602.